دورية أكاديمية
أعرض في EDS

Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence.

التفاصيل البيبلوغرافية
العنوان: Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence.
المؤلفون: El-Gaml RM; Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour City, Egypt., El-Khodary NM; Department of Clinical Pharmacy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh City, Egypt. noha_mahmoud@pharm.kfs.edu.eg., Abozahra RR; Department of Microbiology and Immunology, Faculty of Pharmacy, Damanhour University, Damanhour City, Egypt., El-Tayar AA; Intensive Care Unit, Damanhour National Medical Instititue, Damanhour City, Egypt., El-Masry SM; Department of Pharmaceutics, Faculty of Pharmacy, Damanhour University, Damanhour City, Egypt.
المصدر: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Aug; Vol. 78 (8), pp. 1301-1310. Date of Electronic Publication: 2022 May 25.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer.
مواضيع طبية MeSH: Anti-Bacterial Agents* , Critical Illness*/therapy, Humans ; Infusions, Intravenous ; Linezolid/pharmacology ; Linezolid/therapeutic use ; Microbial Sensitivity Tests ; Prospective Studies
مستخلص: Purpose: Linezolid (LZD) levels are frequently insufficient in intensive care unit (ICU) patients receiving standard dose, which is predictive of a poor prognosis. Alternative dosing regimens are suggested to address these insufficient levels, which are substantial factors contributing to the emergence of multidrug-resistant bacteria, resulting in increased morbidity and mortality among people who are critically ill.
Methods: Forty-eight patients admitted to the intensive care unit were enrolled in an open-label, prospective, randomized study and assigned to one of three LZD administration modes: intermittent groupI (GpI) (600 mg/12 h), continuous infusion groupII (GpII) (1200 mg/24 h) or continuous infusion with loading dose groupIII (GpIII) (on Day 1, 300 mg intravenously plus 900 mg continuous infusion, followed by 1200 mg/24 h on Day 2). We evaluated serum levels of LZD using a validated ultra-performance liquid chromatography (UPLC) technique.
Results: Time spent with a drug concentration more than 85% over the minimum inhibitory concentration (T > MIC) was substantially more common in GpII and III than in GpI (P < 0.01). AUC/MIC values greater than 80 were obtained more frequently with continuous infusion GpIII and GpII than with intermittent infusion GpI, at 62.5%, 37.5% and 25%, respectively (P < 0.01). In GpI, the mortality rate was significantly higher than in the other groups.
Conclusion: In critically ill patients, continuous infusion with a loading dose (GpIII) is obviously superior to continuous infusion without a loading dose (GpII) or intermittent infusion (GpI) for infection therapy. Additionally, it might limit fluctuations in plasma concentrations, which may help overcome LZD resistance.
(© 2022. The Author(s).)
References: Diagn Microbiol Infect Dis. 2004 Feb;48(2):125-30. (PMID: 14972382)
BMJ. 1998 Sep 5;317(7159):645-7. (PMID: 9727994)
Clin Pharmacokinet. 2018 May;57(5):559-575. (PMID: 29063519)
Nat Med. 2004 Dec;10(12 Suppl):S122-9. (PMID: 15577930)
Am J Emerg Med. 2017 Feb;35(2):245-248. (PMID: 27832976)
J Antimicrob Chemother. 2001 Nov;48(5):605-8. (PMID: 11679548)
Drug Res (Stuttg). 2013 Sep;63(9):489-94. (PMID: 23740384)
Nephron. 1976;16(1):31-41. (PMID: 1244564)
Int J Antimicrob Agents. 2008 Feb;31(2):122-9. (PMID: 18055183)
Int J Antimicrob Agents. 2011 Oct;38(4):296-300. (PMID: 21741222)
Intensive Care Med. 2004 Dec;30(12):2145-56. (PMID: 15536528)
Antimicrob Agents Chemother. 2007 Apr;51(4):1287-92. (PMID: 17242144)
Antimicrob Agents Chemother. 2002 Dec;46(12):3706-11. (PMID: 12435665)
Intensive Care Med. 2015 Jan;41(1):103-10. (PMID: 25413377)
Crit Care Med. 2001 Feb;29(2):385-91. (PMID: 11246321)
Crit Care Med. 2005 Jul;33(7):1529-33. (PMID: 16003058)
Int J Antimicrob Agents. 2016 Sep;48(3):259-64. (PMID: 27474469)
Int J Clin Pharmacol Ther. 2015 Sep;53(9):765-71. (PMID: 26227096)
J Antimicrob Chemother. 2003 May;51(5):1239-46. (PMID: 12668582)
Int J Infect Dis. 2014 May;22:35-40. (PMID: 24603161)
Int J Infect Dis. 2020 Apr;93:329-338. (PMID: 32112965)
Antimicrob Agents Chemother. 2002 May;46(5):1475-80. (PMID: 11959585)
Int J Clin Pharmacol Ther Toxicol. 1992;30 Suppl 1:S51-8. (PMID: 1601532)
Clin Pharmacokinet. 2003;42(15):1411-23. (PMID: 14674791)
Expert Rev Anti Infect Ther. 2016 Oct;14(10):901-15. (PMID: 27532292)
فهرسة مساهمة: Keywords: Continuous infusion; ICU patients; LZD; Pharmacodynamics; Pharmacokinetics
المشرفين على المادة: 0 (Anti-Bacterial Agents)
ISQ9I6J12J (Linezolid)
تواريخ الأحداث: Date Created: 20220524 Date Completed: 20220718 Latest Revision: 20220720
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9283351
DOI: 10.1007/s00228-022-03340-z
PMID: 35610318
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1041
DOI:10.1007/s00228-022-03340-z